JP2016531563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531563A5 JP2016531563A5 JP2016525279A JP2016525279A JP2016531563A5 JP 2016531563 A5 JP2016531563 A5 JP 2016531563A5 JP 2016525279 A JP2016525279 A JP 2016525279A JP 2016525279 A JP2016525279 A JP 2016525279A JP 2016531563 A5 JP2016531563 A5 JP 2016531563A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- liver
- hcc
- medicament
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 5
- 239000011724 folic acid Substances 0.000 description 4
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- -1 glucose and mannose Chemical class 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
Description
前記構造式４でのリガンドは、好ましくはターゲット細胞特異的に細胞内在化（ｉｎｔｅｒｎａｌｉｚａｔｉｏｎ）を増進させるＲＭＥ特性を持つターゲット受容体特異的抗体やアプタマー、ペプチド；または、葉酸（Ｆｏｌａｔｅ、一般にｆｏｌａｔｅとｆｏｌｉｃ ａｃｉｄは互いに交差使用されており、本発明での葉酸は、自然状態または人体で活性化状態であるｆｏｌａｔｅを意味する）、Ｎ−アセチルガラクトサミン（Ｎ−ａｃｅｔｙｌ Ｇａｌａｃｔｏｓａｍｉｎｅ，ＮＡＧ）等のヘキソアミン（ｈｅｘｏａｍｉｎｅ）、ブドウ糖（ｇｌｕｃｏｓｅ）、マンノース（ｍａｎｎｏｓｅ）をはじめとする糖や炭水化物（ｃａｒｂｏｈｙｄｒａｔｅ）等の化学物質などで選択されるが、これに限定されるのではない。
Claims (3)
- 請求項１から請求項６のいずれかに記載のｓｉＲＮＡ、請求項７から請求項２１のいずれかに記載の二重らせんオリゴＲＮＡ構造体、請求項２２若しくは請求項２３に記載のナノ粒子、または請求項２４から請求項２８のいずれかに記載の組成物若しくは剤形の、癌の予防または治療用医薬の製造における使用。
- 前記癌は、肝臓癌、胃癌、大腸癌、すい臓癌、前立腺癌、乳癌、卵巣癌、腎臓癌及び肺癌で構成された群から選択されることを特徴とする請求項２９に記載の使用。
- 前記肝臓癌は、ＨＣＣであることを特徴とする請求項３０に記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130080579A KR20150006742A (ko) | 2013-07-09 | 2013-07-09 | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| KR10-2013-0080579 | 2013-07-09 | ||
| PCT/KR2014/006145 WO2015005669A1 (en) | 2013-07-09 | 2014-07-09 | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016531563A JP2016531563A (ja) | 2016-10-13 |
| JP2016531563A5 true JP2016531563A5 (ja) | 2016-12-01 |
Family
ID=52280271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525279A Withdrawn JP2016531563A (ja) | 2013-07-09 | 2014-07-09 | 肝臓癌関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体及びこれを含む癌予防または治療用組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160168573A1 (ja) |
| EP (1) | EP3019611A4 (ja) |
| JP (1) | JP2016531563A (ja) |
| KR (1) | KR20150006742A (ja) |
| CN (1) | CN105765069A (ja) |
| SG (1) | SG11201600076WA (ja) |
| WO (1) | WO2015005669A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116898870A (zh) | 2017-07-28 | 2023-10-20 | 雷莫内克斯生物制药有限公司 | 用于预防或治疗肝癌的药物组合物 |
| CN110964816A (zh) * | 2019-11-20 | 2020-04-07 | 深圳市鲲鹏未来科技有限公司 | 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法 |
| CN111189808B (zh) * | 2019-12-25 | 2022-12-06 | 宁夏医科大学总医院 | 与肝脏损伤、肝细胞凋亡相关特异蛋白分子标志物筛选方法 |
| CN111596059A (zh) * | 2020-05-19 | 2020-08-28 | 上海长海医院 | Gankyrin蛋白作为新型分子标志物在前列腺癌预后评估中的应用 |
| WO2023013818A1 (ko) * | 2021-08-06 | 2023-02-09 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 |
| KR102329524B1 (ko) * | 2021-08-06 | 2021-11-23 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 |
| WO2024081511A2 (en) * | 2022-09-28 | 2024-04-18 | Ohio State Innovation Foundation | Rna complexes and nanostructures for treatment of cancer metastasis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69429337T3 (de) * | 1993-04-02 | 2012-08-30 | Anticancer Inc. | Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US20060078624A1 (en) * | 2004-09-29 | 2006-04-13 | Samuel Zalipsky | Microparticles and nanoparticles containing a lipopolymer |
| AU2008206695A1 (en) * | 2007-01-16 | 2008-07-24 | Proteologics Ltd | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | ｓｉＲＮＡ 접합체 및 그 제조방법 |
| KR101230913B1 (ko) * | 2009-11-06 | 2013-02-07 | 중앙대학교 산학협력단 | 나노입자-기반된 유전자 운반체 |
| BR112014014730B1 (pt) * | 2011-12-15 | 2021-05-18 | Bioneer Corporation | estrutura de droga polímero terapêutica, métodos para preparar uma estrutura de oligo rna de dupla hélice, nanoparticula e composição farmacêutica |
-
2013
- 2013-07-09 KR KR20130080579A patent/KR20150006742A/ko not_active Application Discontinuation
-
2014
- 2014-07-09 SG SG11201600076WA patent/SG11201600076WA/en unknown
- 2014-07-09 WO PCT/KR2014/006145 patent/WO2015005669A1/en active Application Filing
- 2014-07-09 JP JP2016525279A patent/JP2016531563A/ja not_active Withdrawn
- 2014-07-09 US US14/902,808 patent/US20160168573A1/en not_active Abandoned
- 2014-07-09 CN CN201480048986.8A patent/CN105765069A/zh active Pending
- 2014-07-09 EP EP14822311.8A patent/EP3019611A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531563A5 (ja) | ||
| JP2019526543A5 (ja) | ||
| WO2012109624A3 (en) | Monovalent and multivalent multispecific complexes and uses thereof | |
| JP2018513104A5 (ja) | ||
| WO2014135282A8 (en) | Amatoxin derivatives | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| WO2014160160A3 (en) | Antibody drug conjugates and corresponding antibodies | |
| BR112014027952A2 (pt) | anticorpos capazes de se ligar ao fator xi de coagulação e/ou à sua forma ativada fator xia e suas utilizações. | |
| JP2015516989A5 (ja) | ||
| WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | |
| MX344009B (es) | Conjugados de amatoxinas con enlaces mejorados. | |
| PH12015502112A1 (en) | Cancer treatment using antibodies that bind cell surface grp78 | |
| IL240731B (en) | An antibody that binds the p19 subunit of il-23, its production process, a pharmaceutical preparation containing it and its use in cancer treatment | |
| MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
| WO2015058861A8 (en) | Bispecific constructs and their use in the treatment of various diseases | |
| WO2016123591A3 (en) | Compositions and methods for treatment and detection of cancers | |
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| EP2519542A4 (en) | ANTI-CDH3 ANTIBODY AND ITS USE | |
| WO2014169221A3 (en) | Cancer therapy | |
| CL2012002745A1 (es) | Anticuerpos humanizados que se unen a il-25; ácido nucleico aislado que lo codifica; vector de expresión que comprende dicho ácido nucleico; célula huésped que porta dicho vector; método de producción de dicho anticuerpo; composición farmacéutica que lo comprende; y su uso para tratar o prevenir el asma, colitis ulcerativa, enfermedad de crohn o una enfermedad inflamatoria del intestino. | |
| JP2016526021A5 (ja) | ||
| Lee | Guidelines for the treatment of gastroesophageal reflux disease | |
| JP2017532332A5 (ja) | ||
| JP2013100286A5 (ja) | ||
| JP2015500286A5 (ja) |